BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 27122193)

  • 21. Targeting histone methyltransferase EZH2 as cancer treatment.
    Kondo Y
    J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
    Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
    Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategy for "detoxification" of a cancer-derived histone mutant based on mapping its interaction with the methyltransferase PRC2.
    Brown ZZ; Müller MM; Jain SU; Allis CD; Lewis PW; Muir TW
    J Am Chem Soc; 2014 Oct; 136(39):13498-501. PubMed ID: 25180930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of histone methylation by automethylation of PRC2.
    Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR
    Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.
    Antonysamy S; Condon B; Druzina Z; Bonanno JB; Gheyi T; Zhang F; MacEwan I; Zhang A; Ashok S; Rodgers L; Russell M; Gately Luz J
    PLoS One; 2013; 8(12):e84147. PubMed ID: 24367637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
    Bagal SK; Gregson C; O' Donovan DH; Pike KG; Bloecher A; Barton P; Borodovsky A; Code E; Fillery SM; Hsu JH; Kawatkar SP; Li C; Longmire D; Nai Y; Nash SC; Pike A; Robinson J; Read JA; Rawlins PB; Shen M; Tang J; Wang P; Woods H; Williamson B
    J Med Chem; 2021 Dec; 64(23):17146-17183. PubMed ID: 34807608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SAH derived potent and selective EZH2 inhibitors.
    Kung PP; Huang B; Zehnder L; Tatlock J; Bingham P; Krivacic C; Gajiwala K; Diehl W; Yu X; Maegley KA
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1532-7. PubMed ID: 25746813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reaction coupling between wild-type and disease-associated mutant EZH2.
    Swalm BM; Knutson SK; Warholic NM; Jin L; Kuntz KW; Keilhack H; Smith JJ; Pollock RM; Moyer MP; Scott MP; Copeland RA; Wigle TJ
    ACS Chem Biol; 2014 Nov; 9(11):2459-64. PubMed ID: 25154026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
    Yang CY; Wang S
    J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dissecting the role of H3K27 acetylation and methylation in PRC2 mediated control of cellular identity.
    Lavarone E; Barbieri CM; Pasini D
    Nat Commun; 2019 Apr; 10(1):1679. PubMed ID: 30976011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural Basis of the Interaction Between Ubiquitin Specific Protease 7 and Enhancer of Zeste Homolog 2.
    Gagarina V; Bojagora A; Lacdao IK; Luthra N; Pfoh R; Mohseni S; Chaharlangi D; Tan N; Saridakis V
    J Mol Biol; 2020 Feb; 432(4):897-912. PubMed ID: 31866294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.
    Koyen AE; Madden MZ; Park D; Minten EV; Kapoor-Vazirani P; Werner E; Pfister NT; Haji-Seyed-Javadi R; Zhang H; Xu J; Deng N; Duong DM; Pecen TJ; Frazier Z; Nagel ZD; Lazaro JB; Mouw KW; Seyfried NT; Moreno CS; Owonikoko TK; Deng X; Yu DS
    Oncogene; 2020 Jun; 39(25):4798-4813. PubMed ID: 32457468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EZH2 as a potential target in cancer therapy.
    McCabe MT; Creasy CL
    Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting EZH2 for cancer therapy: progress and perspective.
    Han Li C; Chen Y
    Curr Protein Pept Sci; 2015; 16(6):559-70. PubMed ID: 25854924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
    Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
    Zhou B; Liang X; Mei H; Qi S; Jiang Z; Wang A; Zou F; Liu Q; Liu J; Wang W; Hu C; Chen Y; Wang Z; Wang B; Wang L; Liu J; Liu Q
    J Med Chem; 2021 Oct; 64(20):15170-15188. PubMed ID: 34664960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
    Barsotti AM; Ryskin M; Rollins RA
    Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
    [No Abstract]   [Full Text] [Related]  

  • 39. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
    Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
    Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural basis for inactivation of PRC2 by G-quadruplex RNA.
    Song J; Gooding AR; Hemphill WO; Love BD; Robertson A; Yao L; Zon LI; North TE; Kasinath V; Cech TR
    Science; 2023 Sep; 381(6664):1331-1337. PubMed ID: 37733873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.